Fontan Surgery Outcomes by Lung Blood Flow in Single-Ventricle Heart Disease
Compares health after Fontan surgery in people with single-ventricle heart disease.
Key facts
- Who runs it
- Sisca Natalia Siagian
- Where
- Indonesia1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Fontan Outcomes in Oligemia vs Plethora in Univentricular CHD
- Status
- Recruiting
- People taking part
- 52 people, planned
- Started
- 1 Jan 2025
- Expected to end
- Jun 2027
- Type of study
- Observational, 2 groups
- Treatments tested
- Fontan Procedure
- Record updated
- 17 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with cyanotic congenital heart disease (a heart defect from birth that lowers blood oxygen) and a single working heart pumping chamber. They must have a planned series of operations that ends with the Fontan procedure.
- Sex
- All sexes can join.
- Disease stage
- Cyanotic congenital heart disease with univentricular heart physiology (one working pumping chamber). People are grouped by low or high blood flow to the lungs.
- Earlier treatment
- A staged series of operations including the Fontan procedure must be planned.
Main reasons for not taking part
- Refusing to take part
- Incomplete clinical data
- Not able to complete follow-up visits
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Diagnosed cyanotic CHD
- Univentricular heart physiology
- Planned staged palliation including Fontan procedure
- Informed consent obtained (patient or guardian)
Who cannot take part
- Refusal to participate
- Incomplete clinical data
- Inability to complete follow-up
This trial is currently available in Indonesia.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This prospective cohort study evaluates differences in clinical outcomes between pulmonary oligemia and pulmonary plethora in patients with cyanotic congenital heart disease and univentricular heart physiology undergoing staged palliation culminating in the Fontan procedure.Fifty-two patients will be classified into two groups based on pulmonary blood flow characteristics and followed for approximately 1.5 years after the Fontan procedure. Outcomes include mortality, morbidity, pulmonary hemodynamics, functional capacity, neurocognitive status, and quality of life.
The 2 groups in the trial
- Pulmonary Oligemia
Patients with cyanotic CHD and univentricular physiology characterized by reduced pulmonary blood flow.
Treatment: Fontan Procedure
- Pulmonary Plethora
Patients with cyanotic CHD and univentricular physiology characterized by increased pulmonary blood flow.
Treatment: Fontan Procedure
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Comparison of Outcomes of Pulmonary Oligemia Versus Pulmonary Plethora in Cyanotic Congenital Heart Disease With Univentricular Heart After Fontan Procedure
- Plain-language title
- Fontan Surgery Outcomes by Lung Blood Flow in Single-Ventricle Heart DiseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 17 April 2026